Adverum Biotechnologies (Adverum Biotechnologies) 5-Year EBITDA Growth Rate : -3.60% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies 5-Year EBITDA Growth Rate?

Adverum Biotechnologies's EBITDA per Share for the three months ended in Dec. 2023 was $-2.49.

During the past 3 years, the average EBITDA Per Share Growth Rate was 4.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -3.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adverum Biotechnologies was 15.60% per year. The lowest was -172.00% per year. And the median was -0.90% per year.

Competitive Comparison of Adverum Biotechnologies's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Adverum Biotechnologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's 5-Year EBITDA Growth Rate falls into.

Adverum Biotechnologies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Adverum Biotechnologies (NAS:ADVM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Adverum Biotechnologies 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AVU:Germany

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Executives

C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi	officer: Chief Development Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein	officer: Chief Financial Officer	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar	officer: Chief Legal Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley	officer: Chief Scientific Officer	100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer	director, officer: CEO and Director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota	officer: Principal Accounting Officer	ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow	officer: SVP, Genl Counsel, Acting CFO	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza	officer: Chief Financial Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden	director	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063